Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
nivolumab+relatlimab 由新型LAG-3阻断抗体relatlimab与PD-1抑制剂nivolumab组成,适用于治疗成人和≥12岁儿童的不可切除或转移性黑色素瘤,是一种首创的、固定剂量的、双重免疫治疗的药物,是获得监管批准的首个LAG-3阻断抗体组合产品。 黑...
https://www.nejm.org/doi/full/10.1056/NEJMoa2109970 https://www.onclive.com/view/fda-approves-relatlimab-plus-nivolumab-for-unresectable-or-metastatic-melanoma https://europepmc.org/article/pmc/pmc6920665 https://www.healio.com/news/hematology-oncology/20220318/relatlimab-plus-nivolumab-shows-con...
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, with a manageable safety profile, according to the results of the Phase II/III RELATIVITY-047 clinical trial...
2 Tawbi H, Schadendorf D, Lipson E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med. 2022; 386(1):24-34 doi: 10.1056/NEJMoa2109970 3 A study of relatlimab plus nivolumab versus nivolumab alone in participants with advanced melanoma (RELATIVITY...
1. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma.N Engl J Med.2022;386(1):24-34. doi:10.1056/NEJMoa2109970 2. Tawbi HA, Hodi SF, Lipson EJ, et al. Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previou...